Trial Profile
An Open-label Combined Randomized Double-blind, Positive Control Clinical Trial in Subjects Aged 2 Months (Minimum 6 Weeks) and Above to Preliminary Evaluate the Safety and Immunogenicity of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent vaccine conjugate Sinovac Biotech (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Sinovac Biotech
- 11 Jan 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2023.
- 11 Jan 2023 Status changed from not yet recruiting to recruiting.
- 29 Aug 2022 Planned End Date changed from 25 Dec 2023 to 30 Dec 2023.